anoth case market want
growth stori still intact
share trade after-hour despit sale come in-lin street
organ sale ep beat street manag guidanc
reaction remind us stock reaction abbott result last week report
organ growth ep beat believ could anoth case
market want like top line perhap differ composit growth
medsurg drive upsid higher qualiti ep beat tax drove upsid
net/net view chang continu view capabl deliv
above-p growth thu worthi premium pe multipl reiter overweight
would buyer weak
organ sale growth remain broad base management up low-end guidanc rang
organ sale growth sixth consecut quarter
result continu display diversifi model organ growth
orthoped medsurg neurotechnolog spine mako
captur much invest commun attent contributor growth
one rais low end organ growth target
expect organ growth
end market remain healthi commentari call follow discuss
support view continu healthi end-market across segment
highlight continu strength capit sale mako novadaq earli interest
camera also expect modest improv orthoped market
addit call takeaway see kstew call note focu end market
condit outlook mako publish link
minor chang model forecast larg unchang increas
ep price target unchang
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
overweight believ sustain
above-sector revenu growth profil see
multipl driver across three busi
believ deliv margin commit
goal least annual drive least
ep growth given outlook believ
premium pe justifi
growth greater success new product
greater success drive oper margin
downsid case driver includ slowdown
orthoped hospit capital-expenditure market increas
competit knee foreign exchang stronger
us dollar inabl drive margin expans
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
sale line street deliv solid quarter organ
growth ep street estim
high end compani guidanc rang beat
larg function lower tax rate lower bottom end organ sale
growth continu expect oper margin expans
rais low end adjust ep rang net/net noth
chang view continu rate outperform believ stock remain
worthi premium valuat
addit detail quarter
million except per share data chang sale constant currenc organ basi unless otherwis note
organ growth broad base medsurg neurotechnolog
 spine orthoped
knee sale fairli like consensu
estim knee global constant currenc basi
us ou continu take market share
mako anoth solid quarter place robot global vs year ago
note healthi order book broadli result commentari suggest
oper margin y/i larg line expect
posit leverag oper save off-set invest acquisit
dilut latter depress margin re-affirmed
target oper margin expans year
gross margin street consensu headwind
price fx busi mix off-set favor impact
ep high end guidanc rang though
beat reflect lower expect tax rate
sale constant currenc basi organ
gross margin y/i
sg margin y/i result continu focu cost
transform ctg program includ key project focus indirect purchas
share servic benefit off-set impact acquisit
 margin y/i
oper margin y/i
adjust tax rate y/i came full year
guidanc
adjust ep street estim estim
high end guidanc
expect ep time earn releas street estim fx expect neg
impact ep quarter reflect guidanc
stryker expect organ sale growth rang prior fx expect approxim
neg impact sale neg impact ep full year ep guidanc time earn
releas street versu prior guidanc manag continu expect oper margin expans
effect tax rate
actual million salesrptdex barclay stryker corp
 day day incom profit incom incom net incom share barclay stryker corp
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
